目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 EXECUTIVE SUMMARY
1.1.1 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT
1.1.2 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE
1.1.3 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION
1.1.4 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
3.6 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 EXTENDING THE SHELF LIFE OF PRODUCTS
4.2.2 TECHNOLOGICAL DEVELOPMENTS IN PHARMACEUTICAL GLASS PACKAGING
4.2.3 INCREASING DEMAND FROM THE PHARMACEUTICAL INDUSTRY
4.2.4 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINT
4.3.1 GROWING DEMAND FOR PLASTIC PACKAGING
4.3.2 RESTRAINT IMPACT ANALYSIS
4.4 OPPORTUNITY
4.4.1 INCREASING DEMAND IN EMERGING ECONOMIES
4.5 REGULATORY FRAMEWORK
4.5.1 ASPECTS OF PACKAGING
4.5.1.1 GENERAL CONSIDERATIONS
4.5.1.2 COMPLIANCE
4.5.2 PACKAGING MATERIALS AND CLOSURES
4.5.3 QUALITY ASSURANCE ASPECTS OF PACKAGING
4.5.3.1 GENERAL CONSIDERATIONS
4.5.3.2 QUALITY CONTROL
4.5.3.2.1 SAMPLING
4.5.3.2.2 TESTING PROGRAMME
4.5.3.3 INSPECTION AND AUDIT
4.5.3.3.1 RULES
4.5.3.3.2 AUDITS OF SUPPLIERS
4.5.4 PROTECTION OF THE ENVIRONMENT
4.5.4.1 PACKAGING WASTE
4.5.4.2 WASTE POLICIES
4.6 PROFIT MARGIN ANALYSIS
4.7 RELATION BETWEEN CAPACITY UTILIZATION RATE & PRODUCT PRICES
4.7.1 LOW UTILIZATION
4.7.2 FULL UTILIZATION
4.7.3 OVER-UTILIZATION
4.8 CAPAPCITY UTILISATION ANALYSIS
4.8.1 AVERAGE CAPACITY UTILISATION RANGE OF PROMINENT PLAYERS, 2022-2030
4.8.2 ESTIMATED PLANNED AND FORECASTED CAPACITY EXPANSION BY PROMINENT PLAYERS
4.9 COVID-19 IMPACT ANALYSIS
4.9.1 ECONOMIC IMPACT
4.9.1.1 IMPACT ON THE OVERALL PACKAGING INDUSTRY
4.9.2 IMPACT ON PRODUCTION
4.9.3 IMPACT ON GLASS PACKAGING MARKET
4.9.3.1 IMPACT ON SUPPLY CHAIN
4.9.3.2 IMPACT ON RAW MATERIAL
4.9.3.3 CASH FLOW CONSTRAINTS
4.9.4 IMPACT ON WORLD TRADE

5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 RAW MATERIAL SUPPLY
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION CHANNELS
5.1.4 END USERS
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY

6 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY PRODUCT
6.1 OVERVIEW
6.1.1 VIALS
6.1.2 BOTTLES & JARS
6.1.3 CARTRIDGES & SYRINGES
6.1.4 AMPOULES

7 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY MATERIAL TYPE
7.1 OVERVIEW
7.1.1 TYPE I
7.1.2 TYPE II
7.1.3 TYPE III

8 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY APPLICATION
8.1 OVERVIEW
8.1.1 GENERIC DRUGS
8.1.2 BRANDED DRUGS
8.1.3 BIOLOGICAL DRUGS

9 GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 MEXICO
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 REST OF ASIA-PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 ARGENTINA
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 UAE
9.6.2 SAUDI ARABIA
9.6.3 SOUTH AFRICA
9.6.4 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 COMPETITIVE OVERVIEW
10.3 MARKET SHARE ANALYSIS
10.4 COMPETITIVE BENCHMARKING
10.5 GERRESHEIMER AG: LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL PHARMACEUTICAL GLASS PACKAGING MARKET
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCHES/SERVICE DEPLOYMENTS
10.6.2 EXPANSIONS
10.6.3 MERGERS & ACQUISITIONS/INVESTMENTS
10.6.4 PARTNERSHIPS/CONTRACTS & AGREEMENTS

11 COMPANY PROFILES
11.1 GERRESHEIMER AG
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 NIPRO CORPORATION
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 SCHOTT AG
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 SGD PHARMA
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.5 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.6 BORMIOLI PHARMA S.P.A.
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.7 ARDAGH GROUP S.A.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 WEST PHARMACEUTICAL SERVICES, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 PIRAMAL ENTERPRISES LIMITED
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 STOELZLE OBERGLAS GMBH
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.11 ARAB PHARMACEUTICAL GLASS CO.
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.12 ŞİŞECAM GROUP
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCTS OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 SWOT ANALYSIS
11.12.6 KEY STRATEGIES
11.13 OWENS-ILLINOIS INC.
11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL OVERVIEW
11.13.3 PRODUCTS OFFERED
11.13.4 KEY DEVELOPMENTS
11.13.5 SWOT ANALYSIS
11.13.6 KEY STRATEGIES
11.14 BECTON, DICKINSON AND COMPANY
11.14.1 COMPANY OVERVIEW
11.14.2 FINANCIAL OVERVIEW
11.14.3 PRODUCTS OFFERED
11.14.4 KEY DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.14.6 KEY STRATEGIES

12 APPENDIX
12.1 REFERENCE